Eli Lilly's first-quarter revenue jumps 45% to $12.73 billion, fueled by Mounjaro and Zepbound sales. Net income rises 23% to $2.76 billion, with EPS at $3.06. CEO David Ricks high...
Eli Lilly and Co. sees a 13% stock surge after announcing positive phase 3 results for its orforglipron weight-loss and diabetes pill, marking a significant milestone in medical tr...
Eli Lilly and Co. shares surged 13% after announcing positive phase 3 results for orforglipron, a groundbreaking diabetes and weight loss pill. CEO David Ricks praised its safety, ...
Eli Lilly and Co. shares surged 13% after announcing positive phase 3 results for its orforglipron diabetes and weight-loss drug, a potential game-changer in treatment options.
Eli Lilly's stock jumps 13% after announcing positive phase 3 results for orforglipron, a groundbreaking weight-loss and diabetes pill, marking a first in medical innovation with i...
Eli Lilly and Co. shares surged 13% after announcing positive phase 3 results for orforglipron, a groundbreaking weight-loss and diabetes pill. The drug, the first of its kind to c...
Eli Lilly and Co. shares jump 13% after announcing positive phase 3 results for its orforglipron diabetes and weight loss drug, the first small molecule GLP-1 pill to complete such...
Eli Lilly and Co. shares surged over 13% in premarket trading following the announcement of positive phase 3 results for its ACHIEVE-1 weight loss drug, marking a significant miles...
Eli Lilly plans to transform India's pharmaceutical market with innovative treatments for diabetes and obesity, leveraging AI and global expertise to address the country's health c...
Eli Lilly & Co. plans to introduce Mounjaro, its diabetes and weight-loss medication, in China, India, Brazil, and Mexico, targeting up to 900 million patients. The move comes as d...
Eli Lilly and Co. reported a 45% increase in Q4 2024 revenue to $13.5 billion, with net income up 101% to $4.4 billion. The company anticipates 2025 revenue between $58 billion and...
Eli Lilly and Company forecasts a significant revenue increase to $58-61 billion by 2025, driven by strong sales of its diabetes and obesity treatments, Mounjaro and Zepbound. CEO ...
Eli Lilly and Company is reportedly finalizing a $2.5 billion acquisition of Scorpion Therapeutics, with a $1 billion upfront payment and up to $1.5 billion more based on performan...
